Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scottish Funding Wins for Kite’s CAR-T Tecartus & Five Other Products

Executive Summary

A total of six medicines were recommended for use on the National Health Service in Scotland in August.

You may also be interested in...



Tens Of Thousands To Benefit From English Funding Nod For siRNA Cholesterol Drug Leqvio

A landmark population-level agreement between Novartis and the National Health Service for the gene silencing therapy Leqvio is now being implemented following the thumbs up from health technology assessment body NICE.

Kite Strikes CAR-T Access & Discount Deal For Tecartus In England

Health technology assessment body NICE wants Kite to collect more evidence to prove that Tecartus can cure relapsed or refractory mantle cell lymphoma. But in the meantime, it says the CAR-T therapy should be made available on the National Health Service, making UK patients among the first in the world to be offered access to the treatment.

EU CHMP Opinions and MAA Updates

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.

Topics

Related Companies

UsernamePublicRestriction

Register

PS144800

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel